Posted by Michael Wonder on 11 Aug 2022
MHRA grants marketing authorisation for Novartis’ radioligand therapy Pluvicto (lutetium (Lu 177) vipivotide tetraxetan) in advanced prostate cancer in Great Britain
11 August 2022 - Locamet (gozetotide), a PSMA targeted positron emission tomography imaging tracer, has also received a licence from the MHRA for use in imaging prostate cancer in Great Britain; the first diagnostic PSMA imaging tracer to receive this status from the MHRA.
Advanced Accelerator Applications today announced that the MHRA has granted marketing authorisation in Great Britain for lutetium (Lu 177) vipivotide tetraxetan, for the treatment of adult patients with prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.
